354 related articles for article (PubMed ID: 25341542)
1. Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment.
Cekic C; Linden J
Cancer Res; 2014 Dec; 74(24):7239-49. PubMed ID: 25341542
[TBL] [Abstract][Full Text] [Related]
2. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.
Cekic C; Day YJ; Sag D; Linden J
Cancer Res; 2014 Dec; 74(24):7250-9. PubMed ID: 25377469
[TBL] [Abstract][Full Text] [Related]
3. A
Kjaergaard J; Hatfield S; Jones G; Ohta A; Sitkovsky M
J Immunol; 2018 Jul; 201(2):782-791. PubMed ID: 29802128
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models.
Leone RD; Sun IM; Oh MH; Sun IH; Wen J; Englert J; Powell JD
Cancer Immunol Immunother; 2018 Aug; 67(8):1271-1284. PubMed ID: 29923026
[TBL] [Abstract][Full Text] [Related]
5. A2A adenosine receptor protects tumors from antitumor T cells.
Ohta A; Gorelik E; Prasad SJ; Ronchese F; Lukashev D; Wong MK; Huang X; Caldwell S; Liu K; Smith P; Chen JF; Jackson EK; Apasov S; Abrams S; Sitkovsky M
Proc Natl Acad Sci U S A; 2006 Aug; 103(35):13132-7. PubMed ID: 16916931
[TBL] [Abstract][Full Text] [Related]
6. Blockade of adenosine A2A receptor enhances CD8
Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
[TBL] [Abstract][Full Text] [Related]
7. Silencing adenosine A2a receptor enhances dendritic cell-based cancer immunotherapy.
Masjedi A; Ahmadi A; Ghani S; Malakotikhah F; Nabi Afjadi M; Irandoust M; Karoon Kiani F; Heydarzadeh Asl S; Atyabi F; Hassannia H; Hojjat-Farsangi M; Namdar A; Ghalamfarsa G; Jadidi-Niaragh F
Nanomedicine; 2020 Oct; 29():102240. PubMed ID: 32553948
[TBL] [Abstract][Full Text] [Related]
8. Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses.
Beavis PA; Milenkovski N; Henderson MA; John LB; Allard B; Loi S; Kershaw MH; Stagg J; Darcy PK
Cancer Immunol Res; 2015 May; 3(5):506-17. PubMed ID: 25672397
[TBL] [Abstract][Full Text] [Related]
9. Concomitant blockade of A2AR and CTLA-4 by siRNA-loaded polyethylene glycol-chitosan-alginate nanoparticles synergistically enhances antitumor T-cell responses.
Ghasemi-Chaleshtari M; Kiaie SH; Irandoust M; Karami H; Nabi Afjadi M; Ghani S; Aghaei Vanda N; Ghaderi Sede MJ; Ahmadi A; Masjedi A; Hassannia H; Atyabi F; Hojjat-Farsangi M; Namdar A; Ghalamfarsa G; Jadidi-Niaragh F
J Cell Physiol; 2020 Dec; 235(12):10068-10080. PubMed ID: 32488862
[TBL] [Abstract][Full Text] [Related]
10. Adenosine A2B receptor blockade slows growth of bladder and breast tumors.
Cekic C; Sag D; Li Y; Theodorescu D; Strieter RM; Linden J
J Immunol; 2012 Jan; 188(1):198-205. PubMed ID: 22116822
[TBL] [Abstract][Full Text] [Related]
11. A defect in KCa3.1 channel activity limits the ability of CD8
Chimote AA; Balajthy A; Arnold MJ; Newton HS; Hajdu P; Qualtieri J; Wise-Draper T; Conforti L
Sci Signal; 2018 Apr; 11(527):. PubMed ID: 29692361
[TBL] [Abstract][Full Text] [Related]
12. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy.
Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D
J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064
[TBL] [Abstract][Full Text] [Related]
13. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3
Sharma A; Subudhi SK; Blando J; Scutti J; Vence L; Wargo J; Allison JP; Ribas A; Sharma P
Clin Cancer Res; 2019 Feb; 25(4):1233-1238. PubMed ID: 30054281
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor.
Waickman AT; Alme A; Senaldi L; Zarek PE; Horton M; Powell JD
Cancer Immunol Immunother; 2012 Jun; 61(6):917-26. PubMed ID: 22116345
[TBL] [Abstract][Full Text] [Related]
15. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
[TBL] [Abstract][Full Text] [Related]
16. Caffeine promotes anti-tumor immune response during tumor initiation: Involvement of the adenosine A2A receptor.
Eini H; Frishman V; Yulzari R; Kachko L; Lewis EC; Chaimovitz C; Douvdevani A
Biochem Pharmacol; 2015 Nov; 98(1):110-8. PubMed ID: 26296573
[TBL] [Abstract][Full Text] [Related]
17. Immune Alterations in CD8
Ahmad SF; Ansari MA; Nadeem A; Bakheet SA; Mohammad R; Attia SM
Mol Neurobiol; 2018 Mar; 55(3):2603-2616. PubMed ID: 28421534
[TBL] [Abstract][Full Text] [Related]
18. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors.
Beavis PA; Divisekera U; Paget C; Chow MT; John LB; Devaud C; Dwyer K; Stagg J; Smyth MJ; Darcy PK
Proc Natl Acad Sci U S A; 2013 Sep; 110(36):14711-6. PubMed ID: 23964122
[TBL] [Abstract][Full Text] [Related]
19. A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells.
Zarek PE; Huang CT; Lutz ER; Kowalski J; Horton MR; Linden J; Drake CG; Powell JD
Blood; 2008 Jan; 111(1):251-9. PubMed ID: 17909080
[TBL] [Abstract][Full Text] [Related]
20. Receptor desensitization and blockade of the suppressive effects of prostaglandin E(2) and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes.
Su Y; Jackson EK; Gorelik E
Cancer Immunol Immunother; 2011 Jan; 60(1):111-22. PubMed ID: 20960188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
